Melanoma Epitopes Used in Studying Tumor Regression

Nov. 14, 2006 – Although it accounts for only 4% of all skin cancer cases, melanoma is the leading cause of skin cancer deaths1. Several antigens expressed in melanoma cells and recognized by T cells have been identified and used in developing immunization approaches for tumor regression2. These include: MART-1/Melan-A, gp100, Tyrosinase, p15, TRP-1 and beta-catenin2.

AnaSpec, a leading provider of integrated proteomics solutions, offers a broad collection of peptide products for cancer research, including an extensive listing of melanoma immunodominant epitopes and their analogs.

[Ala26]-Melan-A/MART-1 (26-35)
Melan-A/MART-1 (27-35)
Melan-A, MART 1 (26-35)
[Leu27]-Melan-A, MART 1 (26-35)
Melan-A/MART-1 (24-34)
MELAN-A/MART-1 (32-40)
Melanocyte Associated Antigen gp 100 (17-25)
Melanocyte Associated Antigen gp100
gp100 (476-485)
gp100 (570–579)
gp100 (457-466)
gp100 (614–622)
gp100 (639–647)
gp100 (619–627)
gp100 (178-187)
Tyrosinase (146-156)
Tyrosinase (206-214), T9206
[Asp370]-Tyrosinase (368-376)
Tyrosinase (1-9)
(Asn370) tyrosinase (368–376)
Tyrosinase (192-200)
Tyrosinase (56-70)
Tyrosinase (450-462)
Tyrosinase (243-251), core nonamer sequence
Tyrosinase (240-251)

For more information visit www.anaspec.com

References:
1. American Cancer Society: Cancer Facts and Figures—2006. Atlanta GA: American Cancer Society, 2006.
2. Rosenberg, SA. J. National Cancer Inst. 88, 1635 (1996).

— End —